Nephros Inc: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 10, 2023 and accepted by EDGAR at May 10, 2023, 20:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $3.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $1.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $2.1m | us-gaap:GrossProfit |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $239.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $2.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$306.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $1.0k | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $276.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-03-31 | $3.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $8.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $10.9m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $1.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $2.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $8.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-23-016161. Last ingested by Listed: Oct 24, 2026, 15:10 ET. Listed shows no prices and gives no investment advice.